Aegerion Pharmaceuticals (AEGR) 33.40 $AEGR
Quarterly Earnings Releases and Drug Approval Updates - Analyst Notes on Perrigo, AstraZeneca, Valeant, Aegerion and Mylan
PR Newswire - Mon May 12, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Perrigo Co. (NYSE: PRGO), AstraZeneca Plc (NYSE: AZN), Valeant Pharmaceuticals International Inc. (NYSE: VRX), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR) and Mylan Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2325-100free.
Today's Review on Active Stocks -- Research on TripAdvisor, Canadian Solar, American Capital, and Aegerion Pharma
PR Newswire - Thu May 08, 7:30AM CDT
The trading session on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,518.54, up 0.72% and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the day 0.56% higher at 1,878.21. During the trading session, eight out of ten sectors finished on a positive note. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include TripAdvisor Inc. (NASDAQ: TRIP), Canadian Solar Inc. (NASDAQ: CSIQ), American Capital Ltd (NASDAQ: ACAS) and Aegerion Pharmaceuticals Inc (NASDAQ: AEGR). Free technical research on TRIP, CSIQ, ACAS and AEGR can be downloaded upon signing up at:
Why Aegerion Pharmaceuticals Inc. Shares Were Clobbered
Sean Williams, The Motley Fool - Motley Fool - Wed May 07, 5:30PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Aegerion Pharmaceuticals , a...
Nasdaq stocks posting largest percentage decreases
AP - Wed May 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Wed May 07, 3:45PM CDT
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on May 1, 2014, Aegerion granted stock options to purchase an aggregate of 27,750 shares of common stock to 16 new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $45.53, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
Wider-than-Expected Loss at Aegerion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 2:50PM CDT
Aegerion Pharma reported first quarter 2014 net loss per share of 54 cents, wider than the Zacks Consensus Estimate of a loss of 35 cents.
Aegerion Pharmaceuticals Tumbles After a Big Earnings Miss
Leo Sun, The Motley Fool - Motley Fool - Wed May 07, 11:04AM CDT
Shares of Aegerion Pharmaceuticals are down nearly 27% as of this writing after the company reported lackluster first-quarter earnings and lowered its full-year guidance last night. Aegerion reported net...
Aegerion's Rare Disease Drug Launch Stalls
at The Street - Wed May 07, 9:20AM CDT
Aegerion Pharmaceuticals reported weaker-than-expected first quarter Juxtapid sales and reduced 2014 sales guidance. What looked like a fast and promising start to a rare disease drug launch last summer has now stalled, and management's ability to...
Today’s Top Biotech Stories: Aegerion, GW, and Ariad Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed May 07, 8:11AM CDT
Let's take a closer look at three stocks -- Aegerion Pharmaceuticals , GW Pharmaceuticals , and Ariad Pharmaceuticals -- which could make waves across the health care sector this Wednesday morning. Aegerion slumps on weak earnings...
Aegerion Pharmaceuticals Announces First-Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 3:23PM CDT
- Company achieves growth in U.S. business of 24% over prior quarter
Aegerion Pharmaceuticals Announces Webcast of Presentations at Upcoming Investor Conferences
GlobeNewswire - Wed Apr 30, 3:12PM CDT
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in Deutsche Bank 39 Annual Health Care Conference in Boston. Marc Beer, Chief Executive Officer of Aegerion, is scheduled to present on Wednesday, May 7, 2014 at 3:30 p.m. ET.
Aegerion Pharmaceuticals to Announce First Quarter 2014 Financial Results on Tuesday, May 6
GlobeNewswire - Wed Apr 30, 7:30AM CDT
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced that the Company will host a conference call and live audio webcast at 5:00 p.m. EDT on Tuesday, May 6, 2014, to provide a business update and to discuss its first quarter 2014 financial and operating results.
Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free
Aegerion Shares Up on Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 3:30PM CDT
Aegerion Pharma's shares gained 5.7% immediately after the start of a phase III study in Japan to evaluate Juxtapid in HoFH patients.
Today’s Top Health Care Stories: Intuitive Surgical, Aegerion, and Gilead Sciences
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 09, 8:25AM CDT
Lets take a look at three stocks -- Intuitive Surgical , Aegerion , and Gilead Sciences -- which could cause a lot of market buzz across the health care sector this Wednesday morning. Intuitive Surgical's gloomy first quarter...
Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
GlobeNewswire - Wed Apr 09, 8:22AM CDT
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with debilitating rare diseases, today announced that patient enrollment has been initiated in Japan in a clinical trial of lomitapide as an adjunct treatment to reduce low-density lipoprotein cholesterol (LDL-C) in Japanese patients with homozygous familial hypercholesterolemia (HoFH). Last year, Aegerion received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for lomitapide.
Aegerion Pharmaceuticals awards stock options at USD47.11 per share under inducement programme
M2 - Tue Apr 08, 6:52AM CDT
Biopharmaceutical company Aegerion Pharmaceuticals (NasdaqGS:AEGR) revealed on Monday the grant of stock options to purchase an aggregate of 31,620 shares of common stock under the inducement stock option programme.
Rare LDL Cholesterol Disease Sufferers May Soon Have a New Drug
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 12:05PM CDT
An increasing number of pharmaceutical companies in recent years have focused some or all of their research on rare and orphan diseases. Although these diseases have relatively small patient populations, and the research that goes into drug...
Quarterly Earnings Releases and Drug Approval Updates - Analyst Notes on Perrigo, AstraZeneca, Valeant, Aegerion and Mylan
PR Newswire - Mon May 12, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Perrigo Co. (NYSE: PRGO), AstraZeneca Plc (NYSE: AZN), Valeant Pharmaceuticals International Inc. (NYSE: VRX), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR) and Mylan Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2325-100free.
Today's Review on Active Stocks -- Research on TripAdvisor, Canadian Solar, American Capital, and Aegerion Pharma
PR Newswire - Thu May 08, 7:30AM CDT
The trading session on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,518.54, up 0.72% and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the day 0.56% higher at 1,878.21. During the trading session, eight out of ten sectors finished on a positive note. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include TripAdvisor Inc. (NASDAQ: TRIP), Canadian Solar Inc. (NASDAQ: CSIQ), American Capital Ltd (NASDAQ: ACAS) and Aegerion Pharmaceuticals Inc (NASDAQ: AEGR). Free technical research on TRIP, CSIQ, ACAS and AEGR can be downloaded upon signing up at:
Why Aegerion Pharmaceuticals Inc. Shares Were Clobbered
Sean Williams, The Motley Fool - Motley Fool - Wed May 07, 5:30PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Aegerion Pharmaceuticals , a...
Nasdaq stocks posting largest percentage decreases
AP - Wed May 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Wed May 07, 3:45PM CDT
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on May 1, 2014, Aegerion granted stock options to purchase an aggregate of 27,750 shares of common stock to 16 new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $45.53, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
Wider-than-Expected Loss at Aegerion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 2:50PM CDT
Aegerion Pharma reported first quarter 2014 net loss per share of 54 cents, wider than the Zacks Consensus Estimate of a loss of 35 cents.
Aegerion Pharmaceuticals Tumbles After a Big Earnings Miss
Leo Sun, The Motley Fool - Motley Fool - Wed May 07, 11:04AM CDT
Shares of Aegerion Pharmaceuticals are down nearly 27% as of this writing after the company reported lackluster first-quarter earnings and lowered its full-year guidance last night. Aegerion reported net...
Aegerion's Rare Disease Drug Launch Stalls
at The Street - Wed May 07, 9:20AM CDT
Aegerion Pharmaceuticals reported weaker-than-expected first quarter Juxtapid sales and reduced 2014 sales guidance. What looked like a fast and promising start to a rare disease drug launch last summer has now stalled, and management's ability to...
Today’s Top Biotech Stories: Aegerion, GW, and Ariad Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed May 07, 8:11AM CDT
Let's take a closer look at three stocks -- Aegerion Pharmaceuticals , GW Pharmaceuticals , and Ariad Pharmaceuticals -- which could make waves across the health care sector this Wednesday morning. Aegerion slumps on weak earnings...
Aegerion Pharmaceuticals Announces First-Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 3:23PM CDT
- Company achieves growth in U.S. business of 24% over prior quarter
Aegerion Pharmaceuticals Announces Webcast of Presentations at Upcoming Investor Conferences
GlobeNewswire - Wed Apr 30, 3:12PM CDT
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in Deutsche Bank 39 Annual Health Care Conference in Boston. Marc Beer, Chief Executive Officer of Aegerion, is scheduled to present on Wednesday, May 7, 2014 at 3:30 p.m. ET.
Aegerion Pharmaceuticals to Announce First Quarter 2014 Financial Results on Tuesday, May 6
GlobeNewswire - Wed Apr 30, 7:30AM CDT
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced that the Company will host a conference call and live audio webcast at 5:00 p.m. EDT on Tuesday, May 6, 2014, to provide a business update and to discuss its first quarter 2014 financial and operating results.
Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free
Aegerion Shares Up on Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 3:30PM CDT
Aegerion Pharma's shares gained 5.7% immediately after the start of a phase III study in Japan to evaluate Juxtapid in HoFH patients.
Today’s Top Health Care Stories: Intuitive Surgical, Aegerion, and Gilead Sciences
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 09, 8:25AM CDT
Lets take a look at three stocks -- Intuitive Surgical , Aegerion , and Gilead Sciences -- which could cause a lot of market buzz across the health care sector this Wednesday morning. Intuitive Surgical's gloomy first quarter...
Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
GlobeNewswire - Wed Apr 09, 8:22AM CDT
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with debilitating rare diseases, today announced that patient enrollment has been initiated in Japan in a clinical trial of lomitapide as an adjunct treatment to reduce low-density lipoprotein cholesterol (LDL-C) in Japanese patients with homozygous familial hypercholesterolemia (HoFH). Last year, Aegerion received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for lomitapide.
Aegerion Pharmaceuticals awards stock options at USD47.11 per share under inducement programme
M2 - Tue Apr 08, 6:52AM CDT
Biopharmaceutical company Aegerion Pharmaceuticals (NasdaqGS:AEGR) revealed on Monday the grant of stock options to purchase an aggregate of 31,620 shares of common stock under the inducement stock option programme.
Rare LDL Cholesterol Disease Sufferers May Soon Have a New Drug
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 12:05PM CDT
An increasing number of pharmaceutical companies in recent years have focused some or all of their research on rare and orphan diseases. Although these diseases have relatively small patient populations, and the research that goes into drug...
